The Drug Enforcement Administration (DEA) may soon have to defend itself in federal court again after denying access to psilocybin to Washington State physician Sunil
Inspired deeply by the incredible docuseries How to Change Your Mind currently streaming on Netflix, last week we explored the roots of the term ‘psychedelic’,
Per our last article on Delta-8, The Food and Drug Administration (FDA) issued the first round of warning letters to businesses regarding the sale of
There has long been an issue over finding viable opioid addiction treatments that don’t cause the individual to go cold turkey and suffer or turn
The time to address this crisis is long overdue. The lawsuits naming and shaming the architects of this deadly epidemic are making headlines, finally, but Doc Brown sums it up best, “If we don’t change the regulatory process for opioids, it will happen again.”
In the wake of the June 25th decision by the Federal Drug Administration to approve a cannabis-based CBD-rich epilepsy medication from GW Pharma, a new lawsuit has been filed by a medical marijuana user against the federal government.
The plaintiff is essentially calling the FDA as her first witness and this has the federal government tiptoeing through a minefield of their own making.
The FDA’s Center for Drug Evaluation and Research has approved the legal use of CBD for patients ages 2 and up who suffer from very specific conditions: Dravet Syndrome (DS) and Lennox-Gastaut Syndrome (LGS), two severe forms of childhood-onset epilepsy. With so much public support in the US for cannabis legalization – not just CBD legalization – the time is right for a major overhaul.
Always Dank. Never Spam. Sign up today for the free weekly newsletter roundup from the top-shelf source of cannabis news, Beard Bros Pharms!
